SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Follow-Up Questions
Scisparc Ltd의 CEO는 누구입니까?
Mr. Amitay Weiss은 2020부터 회사에 합류한 Scisparc Ltd의 Chief Executive Officer입니다.
SPRC 주식의 가격 성능은 어떻습니까?
SPRC의 현재 가격은 $4.33이며, 전 거래일에 increased 13.37% 하였습니다.
Scisparc Ltd의 주요 사업 주제나 업종은 무엇입니까?
Scisparc Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
